967 related articles for article (PubMed ID: 19528466)
1. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
2. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.
Hegele A; Dalpke A; Barth P; Varga Z; Heeg K; Hofmann R; Olbert P
Anticancer Res; 2004; 24(4):2225-30. PubMed ID: 15330165
[TBL] [Abstract][Full Text] [Related]
3. [Immunostimulatory CpG oligodeoxynucleotides (CpG-ODN) in an orthotopic murine transitional cell carcinoma (TCC) model. Effect on local cytokine expression].
Olbert PJ; Schrader AJ; Hofmann R; Hegele A
Urologe A; 2008 Sep; 47(9):1133-4, 1136. PubMed ID: 18679650
[TBL] [Abstract][Full Text] [Related]
4. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
5. Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides.
Hussain I; Jain VV; Kitagaki K; Businga TR; O'Shaughnessy P; Kline JN
Laryngoscope; 2002 Oct; 112(10):1819-26. PubMed ID: 12368622
[TBL] [Abstract][Full Text] [Related]
6. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
7. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
8. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model.
Hegele A; Dalpke A; Heeg K; Barth P; Varga Z; Hofmann R; Olbert P
Tumour Biol; 2005; 26(5):274-80. PubMed ID: 16103747
[TBL] [Abstract][Full Text] [Related]
10. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
[TBL] [Abstract][Full Text] [Related]
11. [A study on the mechanisms of mycobacterial clearance induced by CpG-oligodeoxynucleotides in mice].
Ren T; Liang YJ; Cai YY; Li CY; Mei J; Yuan ZH; Tao MF; Tian M; Zhao B
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jan; 31(1):46-50. PubMed ID: 18366907
[TBL] [Abstract][Full Text] [Related]
12. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.
Ninalga C; Loskog A; Klevenfeldt M; Essand M; Tötterman TH
J Immunother; 2005; 28(1):20-7. PubMed ID: 15614041
[TBL] [Abstract][Full Text] [Related]
13. Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma.
Zhang G; Cao Y; Xu Y; See WA
Urol Oncol; 2005; 23(6):413-8. PubMed ID: 16301119
[TBL] [Abstract][Full Text] [Related]
14. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release.
Hong Z; Jiang Z; Liangxi W; Guofu D; Ping L; Yongling L; Wendong P; Minghai W
Int Immunopharmacol; 2004 Feb; 4(2):223-34. PubMed ID: 14996414
[TBL] [Abstract][Full Text] [Related]
16. [CpG-ODN instillation boosts ICAM-1 expression in an orthotopic murine UCC model: immunohistochemical evaluation of the local response to immunostimulatory DNA].
Klebe M; Olbert PJ; Hofmann R; Barth PJ; Hegele A
Aktuelle Urol; 2024 Apr; 55(2):154-160. PubMed ID: 33853160
[TBL] [Abstract][Full Text] [Related]
17. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction.
Bleich A; Janus LM; Smoczek A; Westendorf AM; Strauch U; Mähler M; Hedrich HJ; Fichtner-Feigl S; Schölmerich J; Falk W; Hofmann C; Obermeier F
Gastroenterology; 2009 Jan; 136(1):278-87. PubMed ID: 18952084
[TBL] [Abstract][Full Text] [Related]
18. The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1336-42. PubMed ID: 14767344
[TBL] [Abstract][Full Text] [Related]
19. Local therapy with CpG motifs in a murine model of allergic airway inflammation in IFN-beta knock-out mice.
Matheu V; Treschow A; Teige I; Navikas V; Issazadeh-Navikas S
Respir Res; 2005 Mar; 6(1):25. PubMed ID: 15748290
[TBL] [Abstract][Full Text] [Related]
20. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
